Signup for our free newsletter:

Is AzurRx BioPharma (NASDAQ: AZRX) Undervalued or Overvalued?

Written By Wealth Daily Research Team

Posted March 19, 2020

Today is Wednesday, March 18, 2020 and here’s your daily small cap valuation.

AzurRx BioPharma (NASDAQ: AZRX) is a small-cap stock that could have a lot of potential. But it’s hard to value smaller companies like this. Conventional valuation metrics like price-to-earnings (P/E) ratio, profit margin, and return on equity (ROE) may not be available for them.

To get a sense of AzurRx BioPharma’s true valuation, let’s compare it to its industry peers — and to itself one year ago. We’ll look at four small cap valuation metrics…

Price-to-Book Value (P/B) Ratio

AzurRx BioPharma’s price-to-book value (P/B) ratio of 4.855 is 10.46% lower than its industry average of 5.422. That’s good. A low P/B ratio indicates that the company has a solid balance sheet — and that based on its balance sheet, the stock is trading for unusually cheap.

Free Cash Flow Yield (FCF/Enterprise Value)

AzurRx BioPharma’s free cash flow yield (FCF/EV) of -90.42% is 1635.14% lower than its industry average of 5.89%. That’s not good. This metric compares free cash flow (the amount of cash left over after all expenses and capital expenditures have been paid) with enterprise value (a comprehensive alternative to market cap that includes cash and debt).

A low free cash flow yield indicates that a company is performing inefficiently — or that it’s struggling with the debt on its books.

Earnings per Share (EPS) Growth

AzurRx BioPharma has not grown its earnings per share (EPS) in the last year. That’s not good. Negative earnings aren’t the end of the world — they’re fairly common among smaller, newer companies — but if earnings are falling over time, that’s definitely a bad sign.

Gross Margin Growth

AzurRx BioPharma’s gross margin is undefined. That’s not good. This may indicate that the company has failed to file an income statement properly. We have to fault it for this.

The Takeaway

AzurRx BioPharma scored favorably on 1 of our 4 valuation metrics. With this in mind, we believe the stock is slightly overvalued.

Editor’s Note: We’ve been keeping an eye on a set of small-cap stocks that are a better value than AzurRx BioPharma. These stocks have the potential for bigger gains — and they’re far less risky than the speculative small caps many investors gamble on. Enter your email below to learn more.